Targeting AMPK: A new therapeutic opportunity in breast cancer

Sirwan M. Hadad, Stewart Fleming, Alastair M. Thompson

    Research output: Contribution to journalReview article

    127 Citations (Scopus)

    Abstract

    Background: This paper reviews the mammalian Target Of Rapamycin (mTOR) pathway dysregulation in breast cancer, and the current evidence targeting this pathway directly or through activation of AMP-activated protein kinase (AMPK) as an additional therapeutic opportunity for intervention in breast cancer.

    Methods: Relevant articles were identified through computerised searches of Medline and Pubmed. Secondary articles were identified from the reference lists of key papers and by hand searching.

    Results and conclusion: The current consensus to target the AMPK/mTOR pathway in breast cancer is based on in vitro and epidemiological evidences. A low incidence of cancer in diabetic patients on metformin has been explained in vitro by the drug's anti-proliferative effect through activation of AMPK. There is a need to explore the anticancer effects of metformin and the potential to develop the therapeutic avenues offered by targeting the AMPK/mTOR pathway. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

    Original languageEnglish
    Pages (from-to)17
    Number of pages7
    JournalCritical Reviews in Oncology/Hematology
    Volume67
    Issue number1
    DOIs
    Publication statusPublished - Jul 2008

    Keywords

    • cancer
    • breast cancer
    • mTOR
    • AMPK
    • TSC
    • Akt
    • rapamycin
    • metformin
    • ACTIVATED PROTEIN-KINASE
    • RECEPTOR TYROSINE KINASE
    • ACETYL-COA CARBOXYLASE
    • FATTY-ACID SYNTHASE
    • MAMMALIAN TARGET
    • SKELETAL-MUSCLE
    • CELL-PROLIFERATION
    • RAPAMYCIN MTOR
    • LIFE-STYLE
    • LKB1

    Cite this